Exploring the reverse of the coin, alongside the already investigated role of IL‐1β in revitalizing the anti‐tumor CD8+ T cell response, pioneering is in melanoma the demonstrated anti‐tumor role of IL‐1β in inducing the differentiation of IL‐9‐producing CD4+ T‐helper (Th9) cells by exploiting an alternative signaling pathway. The gene discussed is CD8A; the disease is melanoma.